NodThera Secures £28 million ($40 million) Series A Financing
June 25, 2018
NodThera discovers and develops next generation NLRP3 inflammasome inhibitors for the treatment of diseases driven by chronic inflammation Cambridge, UK, 25 June 2018 – NodThera,